Vardenafil (Levitra/Staxyn) Complete Drug-Drug Interaction Profile

How Vardenafil Works and Why Interactions Matter

Vardenafil inhibits PDE5, the enzyme that degrades cyclic guanosine monophosphate (cGMP) in penile smooth muscle. By blocking PDE5, the drug amplifies nitric oxide (NO) signaling and promotes erection during sexual stimulation. This same NO-cGMP pathway is the reason vardenafil's most dangerous interactions exist.

Any drug that independently raises cGMP or NO levels (nitrates, riociguat) can combine with vardenafil to produce life-threatening hypotension. The FDA label for Levitra explicitly warns that "the concomitant use of vardenafil with nitrates in any form is contraindicated" [1]. Vardenafil is metabolized predominantly through hepatic CYP3A4, so any agent that inhibits or induces this enzyme changes plasma exposure in clinically meaningful ways [2]. A 2003 pharmacokinetic study by Rajagopalan et al. showed that co-administration with ketoconazole 200 mg increased vardenafil AUC by 10-fold, a magnitude that makes dose adjustment non-negotiable [3].

The interaction profile also extends to the cardiac conduction system. Vardenafil produces a small but measurable increase in the QTc interval (mean increase of approximately 8 ms at 10 mg), which is not seen with sildenafil or tadalafil at therapeutic doses [1]. This QT effect becomes clinically relevant when vardenafil is paired with other QT-prolonging medications.

Absolute Contraindications: Nitrates and Riociguat

Do not prescribe vardenafil to any patient taking organic nitrates. This is the single most critical interaction in the entire profile.

Nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite) generate NO systemically. When combined with PDE5 inhibition, the resulting surge in cGMP can drop systolic blood pressure by 25 mmHg or more within minutes [4]. The FDA's 2014 drug safety communication reaffirmed that "PDE5 inhibitors, including vardenafil, potentiate the hypotensive effects of nitrates" and that the combination is absolutely contraindicated [1]. A pharmacodynamic study in healthy volunteers found that vardenafil 20 mg plus nitroglycerin 0.4 mg sublingual produced a maximum mean decrease in standing systolic blood pressure of 24.5 mmHg compared to nitroglycerin alone [5].

If a patient on vardenafil develops chest pain, the treating physician cannot administer nitrates for at least 24 hours after the last vardenafil dose. This washout window is shorter than tadalafil's 48 hours but identical in urgency.

Riociguat (Adempas), a soluble guanylate cyclase stimulator used for pulmonary hypertension, works through the same NO-cGMP pathway. The Endocrine Society and the FDA classify riociguat co-administration with any PDE5 inhibitor as contraindicated [6]. There is no safe dose combination.

CYP3A4 Inhibitors: Mandatory Dose Reductions

Because CYP3A4 is vardenafil's primary metabolic pathway, inhibitors of this enzyme cause predictable and sometimes dramatic increases in drug exposure. The FDA label specifies exact dose ceilings for three tiers of inhibitor strength [1].

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, indinavir, saquinavir): vardenafil must not exceed 2.5 mg per 24 hours. Ketoconazole 400 mg daily increased vardenafil Cmax by 4-fold and AUC by 10-fold in a controlled pharmacokinetic study [3]. Ritonavir 600 mg twice daily increased AUC by 49-fold, making it the most potent known vardenafil interaction [2]. HIV patients on protease inhibitor regimens require particular attention. The combination is not contraindicated, but the 2.5 mg ceiling is firm.

Moderate CYP3A4 inhibitors (erythromycin, fluconazole, verapamil, diltiazem, aprepitant): the recommended maximum is 5 mg per 24 hours. Erythromycin 500 mg three times daily increased vardenafil AUC by approximately 4-fold [1]. Grapefruit juice in large quantities also inhibits intestinal CYP3A4, though the FDA label notes the effect is variable and does not assign a specific dose cap [1].

CYP3A4 inducers (rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort) reduce vardenafil levels, potentially below the therapeutic threshold. No formal dose increase recommendation exists. Clinicians should suspect treatment failure in patients on chronic enzyme inducers and consider alternative PDE5 agents or dose timing strategies.

Alpha-Blockers: Timing and Titration Protocol

Alpha-adrenergic blockers prescribed for benign prostatic hyperplasia (BPH) or hypertension interact pharmacodynamically with vardenafil through additive vasodilation. Both drug classes lower blood pressure by relaxing vascular smooth muscle through different receptor targets.

The FDA label specifies that vardenafil should be initiated at 5 mg (not 10 mg) when the patient is on a stable alpha-blocker regimen [1]. "Stable" means the patient has been on a consistent alpha-blocker dose for at least several days. Vardenafil dosing should be separated from the alpha-blocker dose by at least 6 hours to minimize the overlap of peak plasma concentrations.

A 2004 crossover study published in the Journal of Urology found that vardenafil 10 mg combined with tamsulosin 0.4 mg produced clinically significant drops in standing systolic blood pressure in 5 of 21 subjects (24%), with one subject experiencing symptomatic hypotension [7]. Tamsulosin is considered the most uroselective alpha-blocker, yet the interaction was still apparent. With less selective agents (doxazosin, terazosin, prazosin), the hemodynamic effect is more pronounced.

Dr. Harin Padma-Nathan, who contributed to early PDE5 inhibitor trials, noted in a 2004 clinical review that "the combination of PDE5 inhibitors with alpha-blockers requires careful titration and patient education about orthostatic symptoms" [8]. The practical takeaway: start low, separate dosing, and warn the patient to rise slowly from seated or lying positions.

QT Prolongation: Vardenafil's Unique Cardiac Signal

Vardenafil is the only FDA-approved PDE5 inhibitor with a labeled QT prolongation warning. This distinction matters for patients with cardiac comorbidities, which are common in the ED population.

A thorough QT study submitted to the FDA showed that vardenafil 10 mg increased mean QTcF by approximately 8 ms, while the 80 mg supratherapeutic dose increased it by approximately 10 ms [1]. For context, the FDA's threshold of regulatory concern is a mean QTc increase exceeding 5 ms [9]. These changes are modest at therapeutic doses, but they become unpredictable when combined with other QT-prolonging agents.

The FDA label states that vardenafil "should be avoided" in patients taking Class IA antiarrhythmics (quinidine, procainamide) or Class III antiarrhythmics (amiodarone, sotalol) [1]. The orally disintegrating tablet (Staxyn) carries the same warning. Patients with congenital long QT syndrome should not receive vardenafil.

Other QT-prolonging medications that warrant caution include fluoroquinolone antibiotics (moxifloxacin, levofloxacin), certain antipsychotics (haloperidol, ziprasidone), ondansetron at IV doses, and methadone. No formal pharmacokinetic study has examined each combination, but the additive QTc risk is pharmacologically predictable. Dr. Robert Kloner, a cardiologist who has published extensively on PDE5 inhibitor cardiovascular safety, wrote in Circulation that "the QTc prolongation observed with vardenafil, although small, warrants avoidance of co-prescription with drugs known to prolong the QT interval" [10].

Antihypertensives Beyond Alpha-Blockers

Vardenafil lowers blood pressure modestly on its own. Mean reductions of 5 to 6 mmHg systolic and 3 to 4 mmHg diastolic have been documented at the 20 mg dose [1]. This additive hypotensive effect applies across antihypertensive classes.

With amlodipine 5 mg, co-administration of vardenafil 20 mg produced an additional mean decrease of 6 mmHg systolic and 5 mmHg diastolic beyond the effect of amlodipine alone [1]. ACE inhibitors (enalapril), angiotensin receptor blockers (losartan), beta-blockers (atenolol), and thiazide diuretics all showed similar additive reductions in controlled studies referenced in the FDA label [1].

None of these combinations are contraindicated. The clinical management principle is awareness and monitoring. Patients on multi-drug antihypertensive regimens who add vardenafil should be counseled about dizziness, lightheadedness, and the risk of falls, particularly during the first few doses.

One exception to the "generally manageable" rule: patients on combined alpha-blocker plus antihypertensive therapy. The triple vasodilatory load (alpha-blocker plus vardenafil plus another antihypertensive) can produce clinically significant orthostatic hypotension. These patients need the most conservative vardenafil starting dose (5 mg) and the longest interval between medications.

Alcohol and Recreational Substances

Ethanol and vardenafil share vasodilatory properties. A pharmacokinetic study found that vardenafil 20 mg did not alter the pharmacokinetics of alcohol, but the combination produced additive blood pressure reductions [1]. The FDA label recommends that patients be informed about the potential for increased hypotensive effects when combining vardenafil with substantial alcohol intake.

Recreational use of amyl nitrite ("poppers") remains the most dangerous real-world substance interaction. Poppers are organic nitrates. The same absolute contraindication that applies to prescription nitroglycerin applies here. Emergency departments have documented severe hypotension and syncope in men who combined PDE5 inhibitors with inhaled nitrites [11]. Because poppers use is underreported, clinicians prescribing vardenafil should ask about recreational drug use directly.

Cocaine raises both blood pressure and heart rate through sympathomimetic effects, which could theoretically mask the hypotensive signal of an interaction while still stressing the cardiovascular system. No controlled pharmacokinetic data exist for this combination with vardenafil.

Drug Interactions Specific to the Staxyn Formulation

Staxyn (vardenafil orally disintegrating tablet, 10 mg) is not bioequivalent to Levitra 10 mg. The ODT formulation has a higher Cmax (approximately 21% greater) due to pregastric absorption through the oral mucosa [1]. This difference means that interaction magnitude may be slightly amplified with Staxyn compared to the standard tablet at the same milligram dose.

The FDA label notes that Staxyn should not be used interchangeably with Levitra [1]. All CYP3A4 inhibitor dose adjustments listed for Levitra apply to Staxyn, but the starting formulation is only available in the 10 mg strength. A patient who requires a 2.5 mg or 5 mg dose due to CYP3A4 inhibitor co-administration cannot use Staxyn and must switch to the standard tablet.

Other PDE5 Inhibitors and Guanylate Cyclase Stimulators

Combining vardenafil with another PDE5 inhibitor (sildenafil, tadalafil, avanafil) is pharmacologically irrational and potentially dangerous. No additive efficacy has been demonstrated, but additive hypotension and side effects are predictable. The FDA has not needed to issue a formal interaction warning because no clinical scenario supports the combination.

Tadalafil's 17.5-hour half-life creates a practical consideration. A patient switching from daily tadalafil 5 mg to on-demand vardenafil should allow a washout period of at least 3 to 4 half-lives (roughly 3 days) before the first vardenafil dose to avoid overlapping PDE5 inhibition.

Summary of Dose Adjustments by Co-Medication

For practical reference, these are the FDA-labeled dose ceilings when vardenafil is used with interacting drugs.

• Strong CYP3A4 inhibitors (ketoconazole, ritonavir, indinavir, itraconazole, clarithromycin): maximum 2.5 mg per 24 hours [1]
• Moderate CYP3A4 inhibitors (erythromycin): maximum 5 mg per 24 hours [1]
• Alpha-blockers (tamsulosin, doxazosin, terazosin): initiate vardenafil at 5 mg [1]
• Nitrates (any form): absolute contraindication, no safe dose [1]
• Riociguat: absolute contraindication [6]
• Class IA/III antiarrhythmics: avoid combination [1]
• Congenital long QT syndrome: avoid vardenafil [1]

Porst et al. (2003) demonstrated that vardenafil 10 mg and 20 mg were effective for ED in men with diabetes, a population frequently on metformin, insulin, statins, and ACE inhibitors simultaneously [12]. No significant pharmacokinetic interactions were observed with these common co-medications. This finding is reassuring for the typical patient profile, but it does not eliminate the need to screen for the high-risk interactions listed above.